Cargando…
A machine learning model for identifying patients at risk for wild-type transthyretin amyloid cardiomyopathy
Transthyretin amyloid cardiomyopathy, an often unrecognized cause of heart failure, is now treatable with a transthyretin stabilizer. It is therefore important to identify at-risk patients who can undergo targeted testing for earlier diagnosis and treatment, prior to the development of irreversible...
Autores principales: | Huda, Ahsan, Castaño, Adam, Niyogi, Anindita, Schumacher, Jennifer, Stewart, Michelle, Bruno, Marianna, Hu, Mo, Ahmad, Faraz S., Deo, Rahul C., Shah, Sanjiv J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8113237/ https://www.ncbi.nlm.nih.gov/pubmed/33976166 http://dx.doi.org/10.1038/s41467-021-22876-9 |
Ejemplares similares
-
Implementing a Machine-Learning-Adapted Algorithm to Identify Possible Transthyretin Amyloid Cardiomyopathy at an Academic Medical Center
por: Mitchell, Joshua D, et al.
Publicado: (2022) -
Transthyretin amyloid cardiomyopathy in women: frequency, characteristics, and diagnostic challenges
por: Bruno, Marianna, et al.
Publicado: (2020) -
Temporal Trends of Wild-Type Transthyretin Amyloid Cardiomyopathy in the Transthyretin Amyloidosis Outcomes Survey
por: Nativi-Nicolau, Jose, et al.
Publicado: (2021) -
Extrapolation of Survival Benefits in Patients with Transthyretin Amyloid Cardiomyopathy Receiving Tafamidis: Analysis of the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial
por: Li, Benjamin, et al.
Publicado: (2020) -
Standardising Care and Treatment of Transthyretin Amyloid Cardiomyopathy
por: Fontana, Marianna, et al.
Publicado: (2023)